Harmony Biosciences Holdings faces setbacks after a failed trial and sNDA rejection. Click here to find out why HRMY is a ...

US biotechs Acadia Pharma and Harmony Biosciences have both suffered setbacks in phase 3 trials of drugs for rare diseases – ...

New research has found that people with narcolepsy type 1 exhibit patterns of slow brain pulsations that resemble those seen in healthy sleep. The findings, published in PNAS, suggest that orexin—a ...

Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, a potential first-in-class investigational oral orexin ...

Patients with narcolepsy have a significantly greater risk for cardiovascular disease (CVD) and major adverse cardiovascular events (MACE), even after accounting for stimulant use. These findings were ...

A hormone produced by the brain, orexin, may play a central role in the functioning of the brain's glymphatic system, which clears waste, according to a new study from the University of Oulu.

Several drug makers are racing to win approval of a new class of drugs that could transform how the rare sleep disorder is ...

TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house ...

The outlook for some 3 million people with narcolepsy worldwide could soon improve as drugmakers are racing to win approval ...

Narcolepsy affects how you sleep and stay awake. You can feel very sleepy during the day and may suddenly fall asleep without warning. Narcolepsy symptoms can come and go or change over time. Some ...

DUBLIN, Sept. 7, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 ...